Trial Profile

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lisaftoclax (Primary)
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use
Sponsors Ascentage Pharma

Most Recent Events

12 May 2026 According to an Ascentage Pharma media release, data from study will be presented at the 31st Congress of the European Hematology Association (EHA2026).
27 Mar 2026 Planned End Date changed from 1 Dec 2024 to 1 Dec 2027.
27 Mar 2026 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com